Back to Directory Edmund Capparelli Email ecapparelli@ucsd.edu Institution Univ. of California San Diego Address Univ. of California San Diego 9500 Gilman Drive, MC 0760 La Jolla, CA 92093-0760 Request an Update Affiliated Studies IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, and Efficacy of HIVconsvX Vaccines and Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number TBD Research Area Cure Study Status In Development IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Treatment Study Status In Development IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Treatment Study Status Pending IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed P1069: GPO-VIR Z30 DAIDS Number 10620 Research Area Other Study Status Concluded Show All
IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, and Efficacy of HIVconsvX Vaccines and Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number TBD Research Area Cure Study Status In Development
IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Treatment Study Status In Development
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Treatment Study Status Pending
IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States DAIDS Number 38746 Research Area Treatment Study Status Participants Off Study and Primary Analysis Completed